Dr. Pieter Sonneveld on a Prognostic Indicator for Multiple Myeloma

Pieter Sonneveld, MD, PhD
Published: Tuesday, Jul 05, 2016



Pieter Sonneveld, MD, PhD, Head of the Department of Hematology, Erasmus University Medical Center, discusses the SKY92 prognostic indicator (MMPROFILER) for multiple myeloma.
 
Sonneveld and his team collected the DNA of tumors cells of more than 350 newly diagnosed patients with multiple myeloma. They then worked to identify which genes were overactive in the tumor cells of those patients and did a principal component analysis to find out what the most important genes that are relevant for the prognosis of those patients.
 
Ninety-two genes were identified that represent important pathways in multiple myeloma biology, says Sonneveld. Based on this data, a tool was created that can be used to predict the prognosis of individual myeloma patients or cohorts of patients in large clinical trials.
 


Pieter Sonneveld, MD, PhD, Head of the Department of Hematology, Erasmus University Medical Center, discusses the SKY92 prognostic indicator (MMPROFILER) for multiple myeloma.
 
Sonneveld and his team collected the DNA of tumors cells of more than 350 newly diagnosed patients with multiple myeloma. They then worked to identify which genes were overactive in the tumor cells of those patients and did a principal component analysis to find out what the most important genes that are relevant for the prognosis of those patients.
 
Ninety-two genes were identified that represent important pathways in multiple myeloma biology, says Sonneveld. Based on this data, a tool was created that can be used to predict the prognosis of individual myeloma patients or cohorts of patients in large clinical trials.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x